air645
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00658749)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-13 receptor subunit alpha-2ANTISENSE INHIBITOR
IL13RA2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- air645
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00941577 | Phase 2 | Oct 1, 2009 | Altair Therapeutics |
| NCT00658749 | Phase 1 | Apr 1, 2008 | Altair Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altair Therapeutics | For profit | 2 | 2 | 2 | 2008 |
1 organizations
Page 1 / 1